Analytical validation of Illumina's TruSight Oncology 500 ctDNA assay

被引：4
|
作者：
Verhein, Kirsten C. [1 ]
Hariani, Gunjan [1 ]
Hastings, Stephanie B. [1 ]
Hurban, Patrick [1 ]
机构：
[1] Q Squared Solut, Morrisville, NC USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-3114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3114
引用
收藏
页数：2
相关论文
共 50 条
  • [31] TruSight Oncology 500: Measuring Tumor Mutation Burden with Targeted Sequencing
    Ju, J.
    Jiang, T.
    Zhang, S.
    Berry, G.
    Fu, Y.
    Kaplan, S.
    Yao, J.
    Johansen, S.
    Crain, B.
    Salmans, M.
    Le, P.
    Jager, A. C.
    Zhao, C.
    Bilke, S.
    Pawlowski, T.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (06): : 972 - 972
  • [32] Validation of the Illumina TruSight Tumor Panel for Clinical Testing of Somatic Mutations in Solid Tumors
    Patel, N. M.
    Weck, K. E.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 747 - 748
  • [33] Oncogenic Drivers of Pulmonary Invasive Mucinous Adenocarcinoma, Detected by Trusight Oncology 500
    Shinada, K.
    Hiroshima, Y.
    Murakami, S.
    Narita, A.
    Katakura, S.
    Kondo, T.
    Kato, T.
    Ito, H.
    Yokose, T.
    Saito, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S483 - S483
  • [34] Analytical and clinical validation of a ctDNA-based assay for multi-cancer detection
    Tran, L. S.
    Nguyen, L. H. D.
    Nguyen, T. H. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1467 - S1467
  • [35] Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab
    Wei, Bo
    Kang, John
    Kibukawa, Miho
    Arreaza, Gladys
    Maguire, Maureen
    Chen, Lei
    Qiu, Ping
    Lang, Lixin
    Aurora-Garg, Deepti
    Cristescu, Razvan
    Levitan, Diane
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (06): : 600 - 608
  • [36] EVALUATION OF THE TRUSIGHT ONCOLOGY 500 ASSAY FOR ROUTINE CLINICAL TESTING OF TUMOR MUTATIONAL BURDEN (TMB) AND CLINICAL UTILITY FOR PREDICTING RESPONSE TO PEMBROLIZUMAB
    Wei, Bo
    Kang, John
    Kibukawa, Miho
    Arreaza, Gladys
    Maguire, Maureen
    Chen, Lei
    Qiu, Ping
    Lang, Lixin
    Aurora-Garg, Deepti
    Cristescu, Razvan
    Levitan, Diane
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A49 - A50
  • [37] LabChip GX Touch microfluidics technology to assess RNA quality for the Illumina TruSight Tumor 170 Assay
    Deharvengt, S. J.
    Tafe, L.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1247 - 1247
  • [38] TARGETED GENE SEQUENCING OF SPORADIC YOUNG-ONSET COLON CANCER SAMPLES USING TRUSIGHT ONCOLOGY 500 FROM ILLUMINA IDENTIFIES RECURRENT MUTATIONS IN DDR2 ONCOGENE
    Atikukke, Eesha
    Velisala, Pranita
    ElKeilani, Akram
    Orlando, Julianna
    Cavallo-Medved, Dora
    Rueda, Luis
    Ravid, Anat
    Elfiki, Tarek
    Alkhateeb, Abedalrhman
    Fetz, Andrew
    Porter, Lisa A.
    Atikukke, Govindaraja
    Misra, Sabeena
    GASTROENTEROLOGY, 2024, 166 (05) : S668 - S669
  • [39] DEVELOPMENT OF NEXT GENERATION SEQUENCING AUTOMATION FOR ILLUMINA'S TRUSIGHT HLA SEQUENCING PANEL.
    Iglehart, Brian
    Jackson, Annette
    HUMAN IMMUNOLOGY, 2015, 76 : 98 - 99
  • [40] Assessment of Tumor Mutational Burden and Microsatellite Instability with Illumina's TruSight Tumor 170 Panel
    Zhang, S.
    So, A. S.
    Kaplan, S.
    Yao, J.
    Kruglyak, K. M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1023 - 1024
12345